Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure

Journal of Immunology

Volumn 161, Issue 5, 1998, Pages 2524-2532

  Witko Sarsat, Véronique ^a   Friedlander, Miriam ^b   Khoa, Thao Nguyen ^a   Capeillère Blandin, Chantal ^c   Nguyen, Anh Thu ^a   Canteloup, Sandrine ^a   Dayer, Jean Michel ^d   Jungers, Paul ^a   Drücke, Tilman ^a   Descamps Latscha, Béatrice ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c CNRS   (France)

^d UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD23 ANTIGEN; GLUTATHIONE PEROXIDASE; HUMAN SERUM ALBUMIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2 RECEPTOR; MALONALDEHYDE; NEOPTERIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; DIALYSIS; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MONOCYTE; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY BURST; T LYMPHOCYTE ACTIVATION; UREMIA;

ADULT; BIOLOGICAL MARKERS; CYTOKINES; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MACROPHAGE ACTIVATION; MONOCYTES; OXIDATIVE STRESS; PHENYLALANINE; RESPIRATORY BURST; SERUM ALBUMIN;

EID: 18844471606     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Descamps-Latscha, B. 1993. The immune system in end-stage renal disease. Curr. Opin. Nephrol. Hypertens. 2:883.
2. Dinarello, C. A. 1992. Cytokines: agents provocateurs in hemodialysis? Kidney Int. 41:683.
3. Pereira, B. J. G., L. Shapiro, A. J. King, M. E. Falagas, J. A. Strom, and C. A. Dinarello. 1994. Plasma levels of IL1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 45:890.
4. Descamps-Latscha, B., A. Herbelin, A. T. Nguyen, P. Roux-Lombard, J. Zingraff, A. Moynot, C. Verger, D. Dahmane, D. de Groote, P. Jungers, and J. M. Dayer. 1995. Balance between IL-1β, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis: relationships with activation markers of T cells, B cells, and monocytes. J. Immunol. 154:882.
5. Descamps-Latscha, B., and P. Jungers. 1996. Immunological and chronic inflammatory abnormalities in end stage renal disease. In Replacement of Renal Function by Dialysis. C. Jacobs, C. M. Kjellstrand, K. M. Koch, and J. F. Winchester, eds. Kluwer, Dordrecht, Boston, p. 1083.
6. Richard, M. J., J. Arnaud, C. Jurkovitz, T. Hachache, H. Meftahi, F. Laporte, M. Foret, A. Favier, and D. Cordonnier. 1991. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 57:10.
7. Céballos-Picot I, V. Witko-Sarsat, M. Mérad-Boudia, A. T. Nguyen, M. Thévenin, M. C. Jaudon, J. Zingraff, P. Jungers, and B. Descamps-Latscha. 1996. Glutathione antioxidant system as a marker of uremia progression and oxidative stress in chronic renal failure. Free Radical Biol. Med. 21:845.
8. Van Ypersele de Strihou, C., M. Jadoul, J. Malghem, B. Maldague, and J. Jamart. 1991. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. Kidney Int. 39:1012.
9. Capeillère-Blandin, C., T. Delaveau, and B. Descamps-Latscha. 1991. Structural modifications of human β2 microglobulin treated with oxygen-derived radicals. Biochem. J. 277:175.
10. Linder, A., B. Charra, D. J. Sherrard, and B. H. Scribner. 1974. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N. Engl. J. Med. 290: 698.
11. Maggi, E., R. Bellazzi, F. Falaschi, A. Frattoni, G. Perani, G. Finardi, A. Gazo, M. Nai, D. Romanini, and G. Bellomo. 1994. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int. 45:876.
12. Becker, B. M., J. Himmerlfarb, W. L. Henrich, and R. M. Hakim. 1997. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J. Am. Soc. Nephrol. 8:475.
13. Davies, K. J. 1987. Protein damage and degradation by oxygen radicals. I. General aspects. J. Biol. Chem. 262:9895.
14. Davies, K. J., and A. L. Goldberg. 1987. Oxygen radicals stimulate intracellular proteolysis and lipid peroxidation by independent mechanisms in erythrocytes. J. Biol. Chem. 262:8220.
15. Dean, R. T., S. Fu, R. Stocker, and M. J. Davies. 1997. Biochemistry and pa4 thology of radical-mediated protein oxidation. Biochem. J. 324:1.
16. Heinecke, J. W., W. Li, H. L. Daehnke, and J. A. Goldstein. 1993. Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J. Biol. Chem. 268: 4069.
17. Witko-Sarsat, V., M. Friedlander, C. Capeillère-Blandin, T. Nguyen-Khoa, A. T. Nguyen, J. Zingraff, P. Jungers, and B. Descamps-Latscha. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 49:1304.
18. Vanholder, R., S. Ringoir, A. Dhondt, and R. M. Hakim. 1991. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney Int. 39:320.
19. Ritz, E., R. Deppish, and P. Nawroth. 1994. Toxicity of uraemia - does it come of AGE? Nephrol. Dial. Transplant. 9:1.
20. Makita, Z., R. Bucala, E. J. Rayfield, E. A. Friedman, A. M. Kaufman, S. M. Korbet, R. H. Barth, J. A. Winston, H. Fuh, K. R. Manogue, and A. Cerami. 1994. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 343:1519.
21. Miyata, T., R. Inagi, Y. Iida, M. Sato, N. Yamada, O. Oda, K. Maeda, and H. Seo. 1994. Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin-1. J. Clin. Invest. 93:521.
22. Niwa, T., S. Miyazaki, T. Katsuzaki, N. Tatemichi, Y. Takei, T. Miyazaki, T. Morita, and Y. Hirasawa. 1995. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int. 48:771.
23. Friedlander, M. A., Y. C. Wu, A. Elgawish, and V. M. Monnier. 1996. Early and advanced glycosylation end products: kinetics of formation and clearance in peri-toneal dialysis. J. Clin. Invest. 97:728.
24. Monnier, V. M., D. R. Sell, R. H. Nagaraj, S. Miyata, S. Grandhee, P. Odetti, and S. A. Ibrahim. 1992. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 41(Suppl. 2):36.
25. Miyata, T., Y. Wada, Z. Cai, Y. Iida, K. Horie, Y. Yasuda, K. Maeda, K. Kurokawa, and C. Van Ypersele de Strihou. 1997. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int. 51:1170.
26. Friedlander, M. A., V. Wuko-Sarsat, A. T. Nguyen, Y. C Wu, M. Labrunie, C. Verger, P. Jungers, and B. Descamps-Latscha. 1996. The advanced glycation endproduct pentosidine and monocyte activation in uremia. Clin. Nephrol. 45: 379.
27. Witko, V., A. T. Nguyen, and B. Descamps-Latscha. 1992. Microtiter plate assay for phagocyte-derived taurine-chloramines. J. Clin. Lab. Anal. 6:47.
28. Anderson, S. O. 1966. Covalent cross-links in a structural protein, resilin. Acta Physiol. Scand. 263:1.
29. Bayse, G. S., A. W. Michaels, and M. Morrisson. 1972. The peroxidase-catalyzed oxidation of tyrosine. Biochim. Biophys. Acta 284:34.
30. Amado, R., R. Aeschbach, and H. Neukom. 1984. Dityrosine: in vitro production and characterization. Methods Enzymol. 107:377.
31. Resnik, A. Z., and L. Packer. 1994. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol. 233:357.
32. Odetti, P., J. Fogarty. D. R. Sell, and V. M. Monnier. 1992. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41:153.
33. Sell, D. R., and V. M. Monnier. 1989. Structure elucidation of a senescence cross-link from human extracellular matrix: implication of pentoses in the aging process. J. Biol. Chem. 264:21597.
34. Anderson, M. E. 1985. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol. 113:548.
35. Roux-Lombard, P., L. Punzi, F. Hasler, S. Bas, S. Todesco, H. Gallati, P. A. Guerne, and J. M. Dayer. 1993. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum. 36:485.
36. Allen, R.C. 1986. Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. Methods Enzymol. 133:449.
37. Vilde J. L., V. Witko-Sarsat, D. Salmon-Ceron, J. Saba, C. Mandet, and B. Descamps-Latscha. 1995. Persistence of active oxidation of serum proteins in patients receiving dapsone for secondary prophylaxis of pneumocystosis. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. ICAAC, San Francisco, p. 237.
38. Kawamura, M., J. W. Heinecke, and A. Chait. 1994. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J. Clin. Invest. 94:771.
39. Klebanoff, S. J. 1969. Myeloperoxidase-halide-hydrogen peroxide antibacterial system. J. Bacteriol. 95:2131.
40. Anderson, M. M., S. L. Hazen, F. F. Hsu, and J. W. Heinecke. 1997. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein: a mechanism for the generation of highly reactive α-hydroxy and α, β-unsaturated aldehydes by phagocytes at sites of inflammation. J. Clin. Invest. 99: 424.
41. Leeuwenburgh, C., J. E. Rasmussen, F. F. Hsu, D. M. Mueller, S. Pennathur, and J. W. Heinecke. 1997. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J. Biol. Chem. 272:3520.
42. Daugherty, A., J. L. Dunn, D. L. Rateri, and J. W. Heinecke. 1994. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest. 94:437.
43. Miyata, T., K. Maeda, K. Kurokawa, and C. van Ypersele de Strihou. 1997. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol. Dial. Transplant. 12:255.
44. Vlassara, H., M. Brownlee, and A. Cerami. 1988. Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo. Diabetes 37:456.
45. Schmidt, A. M., R. Mora, R. Cao, S. D. Van, J. Brett, R. Ramakrishnan, T. C. Tsang, M. Simionescu, and D. Stern. 1994. The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J. Biol. Chem. 269:9882.
46. Vlassara, H., L. Moldawer, and B. Chan. 1989. Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor. J. Clin. Invest. 84:1813.
47. Witko-Sarsat, V., and B. Descamps-Latscha. 1997. Advanced oxidation protein products: novel uraemic toxins and pro-inflammatory mediators in chronic renal failure? Nephrol. Dial. Transplant. 12:1310.